Clinical Trial

Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

Study acronym: LONGIST
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-24.
Status change: Not Yet Recruiting → Recruiting 2026-04-02
Trial Details
NCT Number NCT07096609
Lead Sponsor Asan Medical Center
Conditions GIST
Enrollment 48 participants
Start Date 2025-10-29
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-03